SEATTLE (January 4, 2013) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting "active" immune response against diseases, announced today that Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer, will be presenting at the Biotech Showcase™ 2013 Conference being held in San Francisco, Calif.
Etubics will present upon the results of its Phase IIa clinical trial for colorectal cancer immunotherapy aimed at late-stage metastatic patients. The presentation will be held on:
Date: Wednesday, January 9, 2013
Time: 9:30 a.m.
Location: Mission I Room: Parc 55 Wyndham San Francisco Union Square Hotel
Etubics will be entering a randomized Phase IIb clinical trial with its immunotherapeutic product candidate to treat advanced colorectal cancer in early 2013. Etubics Phase I/II colorectal cancer trial has been funded primarily through grants and contracts from the National Cancer Institute (NCI) to the Company. The NCI also awarded earlier grants to Etubics for its colorectal and breast cancer pre-clinical and colorectal clinical work. In addition, the NCI has awarded Etubics a $1.5 million contract to manufacture ETBX-011 for the next clinical trial.
Etubics is developing next generation vaccines and immunotherapy product candidates, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. The Etubics Platform delivers a long lasting "active" immune response against diseases and induces Cell Mediated Immunity (CMI). The Company believes that its Platform enables the rapid expansion of its pipeline of immunotherapeutic drugs for a wide variety of cancers and vaccines for difficult o treat infectious diseases.
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its fifth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers. www.etubics.com
About Demy-Colton Life Science Advisors
Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Now going into its fifth year, Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter. For more information please visit www.demy-colton.com.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. For more information please visit www.ebdgroup.com or follow EBD Group on Twitter at twitter.com/ebdgroup.
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Etubics proposed candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.